Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath
Advertisement
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, is a clinical professor of hematology, of the Faculty of Medicine & Health Sciences, at the University of Nottingham (Centre for Cancer Sciences, Academic Unit of Translational Medical Sciences, School of Medicine).
Articles by Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5